UGent spin-off Indigo Diabetes Initiates First Clinical Study of its Continuous Glucose Monitoring Sensor

(10-05-2021) Ground-breaking subcutaneous sensor aims to continuously monitor multiple metabolites including ketones in people living with diabetes

 Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, announces that its continuous multi-metabolite (‘CMM’) sensor has been successfully implanted subcutaneously in the first three participants of its first clinical study, designed to evaluate the device. Indigo’s CMM sensor is in development for the continuous measurement of glucose, ketone and lactate levels in people living with diabetes. Read more